On May 18, a U.S. jury found Takeda Pharmaceutical liable for approximately $885 million in damages for delaying a generic version of its drug Amitiza. This ruling is part of an antitrust case focusing on Takeda's market practices.
The pharmaceutical giant filed a federal lawsuit against church officials and businessmen for allegedly exploiting Trulicity rebate systems.
Read the full storyThe DOJ has indicted four major Chinese manufacturers for allegedly colluding to restrict supply and inflate shipping container prices during the pandemic.
Law firm Hagens Berman announced that a U.S. jury has awarded $474 million in damages in a class-action lawsuit against Takeda Pharmaceutical.